AIDS, Vienna 2010 MOAA01 Novel therapeutic strategies The LEDGINs: rational design of first in class LEDGF/p75-integrase inhibitors with potent antiviral.

Slides:

Advertisements

Similar presentations

The Drug Discovery Process

Advertisements

AIDS2012 TUAA0301 Pre-clinical Evaluation of HIV Replication Inhibitors that Target the HIV Integrase- LEDGF/p75 Interaction Frauke Christ, Chris Pickford,

Chemical Biology 1 – Pharmacology Methods for studying protein function – Loss of Function 1. Gene knockouts 2. Conditional knockouts 3. RNAi.

1 Applied Biosciences Professional Science Masters Program, Track in Medical and Diagnostic Laboratory Sciences, University of Arizona, Tucson, AZ; 2 Department.

The gp41 fragment (purple) consists of a cytoplasmic tail and a hydrophobic membrane-spanning domain and is joined with the larger gp120 component (blue.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):

Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.

Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.

Biol518 Lecture 2 HTS and Antibiotic Drug Discovery.

1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.

HIV Structure, Lifecycle, and Replication

I guess you think you know this story.

Anti-HIV Drugs Cathy Molina November 11, Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to.

Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.

Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.

The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.

Future directions in HIV basic science research The hunt for a cure.

Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.

1 Discovering new drugs in Africa Defeating Malaria Together Kelly Chibale PhD FRSSAf University of Cape Town.

Identification of New Inhibitors of Plasmodium falciparum Enoyl- ACP Reductase Symposium on: Advances in Parasitology “Education and Research in Parasitology.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.

1 BE : An Inhibitor of DNA –Topoisomerase II Indira Thapa November 24, 2005.

DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.

1 Novel HIV Suppressive Approaches with Integrase Inhibitors Mark A Wainberg McGill University AIDS Centre Montreal, Canada.

Novel Inhibitors of Indoleamine 2,3-Dioxygenase (IDO), a Target for Anti-Cancer Immunotherapy Introduction. Immunotherapy is a promising novel strategy.

Anti-HIV Drugs Melissa Morgan Medicinal Chemistry November 23, 2004.

Project 1: Anti-HIV Mechanisms of NK-1R Antagonists PI: Wenzhe Ho Co-PI: Steven D. Douglas.

Screening Methods Lecture – 4 Tahir. Early screening strategies tends to be empirical, labour intensive and low success rates. As the no of commercially.

Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.

XVIII International AIDS Conference Novel HIV-1 Protease Inhibitors Containing bis-Tetrahydrofuran or a Novel Polycyclic Ligand, Pyranofuran 1 Depts of.

Triplex forming oligonucleotides (TFO)

Targeting Protein Phosphatase-1 for the Inhibition of HIV-1 Sergei Nekhai, Ph.D. NIGMS, NIH RCMI –NCRR NHLBI, NIH Civilian Research and Development Foundation.

HIV Life Cycle Step 1: Fusion Step 2: Transcription reverse transcriptase Step 3: Integration Step 4: Cleavage Step 5: Packaging and Budding HIV.

Nitrones as potential therapeutic agents against Alzheimer’s Disease Dra. Alicia Merlino, Computational Chemistry Lab, Facultad de Ciencias, Universidad.

In vitro activity of candidate microbicides against cell-associated HIV Philippe Selhorst, Katrijn Grupping, Johan Michiels, Kevin Ariën and Guido Vanham.

HCV Protease Yasir Waheed. Discovery of Hepatitis C.

Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.

Insilico design, synthesis and biological evaluation of inhibitors of hypoxia- inducible factor (HIF-1) as antitumor agents Lucía Minini, Maira De Negri,

항바이러스제 Ritonavir 양혜란. Ritonavir 화학명 1,3-Tiazol-5-ylmethyl[3-hydroxy-5-[3-methyl-2-[methyl-[(2-propan-2- yl-1,3-thiazole-4-yl)methyl]carbamoyl]-aminobutanoyl]amino-1,6-

Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.

Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Role.

Pharmaceutical Approaches to Antiviral Drug Discovery

Molecular Modeling in Drug Discovery: an Overview

Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.

Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.

1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 1: Sections

Volume 18, Issue 3, Pages (March 2010)

Identification of FoxO1 inhibitors using large scale transiently transfected assay-ready cells in HTS Tyrrell Norris1, Elke Ericson1, Jennifer Hicks1,

Effect of inhibitor binding on the 1H-15N HSQC spectra of RGS4.

PBMCs from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors show variable susceptibility to HIV-1 infection: searching.

An Introduction to Medicinal Chemistry 3/e

LncRNAs exert their effects by diverse mechanisms. LncRNAs exert their effects by diverse mechanisms. (A) lncRNAs can.

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

HIV Integrase Therapeutics

Structure and Function Laura Martin

Structure and Function Laura Martin

Structure and Function Laura Martin

Figure 4 Potential therapeutic strategies to inhibit TGF-β1/Smad-induced tissue fibrosis Figure 4 | Potential therapeutic strategies to inhibit TGF-β1/Smad-induced.

Miquel Duran-Frigola, Roberto Mosca, Patrick Aloy Chemistry & Biology

Volume 20, Issue 5, Pages (May 2012)

Transportin-SR2 Imports HIV into the Nucleus

Volume 20, Issue 11, Pages (November 2012)

Targeting MgrA-Mediated Virulence Regulation in Staphylococcus aureus

Interactions between Retroviruses and the Host Cell Genome

Michelle R. Arkin, Yinyan Tang, James A. Wells Chemistry & Biology

Antimicrobials and Antimicrobial Resistance

Tertiary structures of viral integrase and chemical formulas of HIV integrase inhibitors. Tertiary structures of viral integrase and chemical formulas.

성균관대학교 약학과 김연수

Presentation transcript:

AIDS, Vienna 2010 MOAA01 Novel therapeutic strategies The LEDGINs: rational design of first in class LEDGF/p75-integrase inhibitors with potent antiviral activity Frauke Christ Molecular Virology and Gene Therapy Catholic University Leuven Belgium

LEDGF/p75 in HIV replication Nucleus Cytoplasm Reverse transcription complex Preintegration complex (PIC) TRN-SR2 LEDGF/p75 IN LEDGF/p75 IN 2003LEDGF/p75 is a co-factor of HIV replication (Cherepanov et al., J. Biol. Chem.) LEDGF/p75 tethers IN to the chromatin (Maertens et al., J. Biol. Chem. 2003, Ciuffi et al., Nature Medicine, 2005, Llano et al., Science 2006) 2006Overexpression of the LEDGF/p75 integrase binding domain (IBD) inhibits HIV replication (De Rijck et al., J. Virol.)

Rational design of LEDGINs CCD+IBD CCD+small molecule CCD+CCD SuperpositionInputConsensus pharmacophore Collection of features which are present in 3 or more structures resulted in 16 features constructing the initial pharmacophore

From in silico towards in cellulo CX00287 CX CX00482 Moderate in vitro activity (36% inhibition at 100µM) AlphaScreen IC 50 = µM AlphaScreen IC 50 = 12.2+/-3.4 µM MTT/MT-4 EC 50 =41.9+/-1.1µM CC 50 >150µM 25 initial hit structures from in silico screening Molecular modeling Optimization by medicinal chemistry

Optimization of 2-(quinolin-3-yl)acetic acids (LEDGINs) AlphaScreen TM (IC 50 in µM) ELISA (IC 50 in µM) MTT/MT-4 [µM] LEDGF/p75- IN LEDGF/p75- JPO2 LEDGF/p75- PogZ IN-DNAIN-IN IN-Strand transfer EC 50 CC 50 SI CX CX / /-1.1>150>3 CX /-0.8>>100 > / /-2.56 CX /-2.8>>100 > / /-6.56 CX /-0.4>> / / / CX CX00482 CX01978 CX04328 In addition LEDGINs are active in primary PBMCs and macrophages.

LEDGINs inhibit HIV replication at the integration step no inhibition CX04328 raltegravir AZT Late RT 2LTRsproviral DNA

LEDGINs profile as integrase inhibitors during TOA* * Time of addition In combination experiments strand transfer inhibitors and LEDGINs behave neither synergistic nor antagonistic but additive. LEDGINs might be used in combination therapy.

Crossresistance profile of CX04328 ResistanceVirus strain CX004328raltegravirelvitegravirAZT AMD 3100 Efavirenz IBDA128T/E170G >17*11211 raltegravirE92Q Q148H N155H G140S/Q148H L74M/F121Y/D 232N AZTRTMC AMD EfavirenzA17RIIIB * fold resistance with respect to the activity against the wt-strain

Resistance selection (CX04328) 125 T V K 128 A A C 131 W ACA GTT AAG GCC GCC TGT TGG ACA GTT AAG ACC GCC TGT TGG NL4.3 HIV-1 integrase Passage #18 (13 x IC 50 ) Passage #29 (17.5 x IC 50 ) 125 T V K 128 T A C 131 W GAA GTA AAG ATG GTA GCA TGG 125 E V K 128 M V A 131 W HIV-2 integrase (13%) (63%) (90%) (99%) IN A128T IN A128T (passage #40) is >10 fold resistant to CX04328

LEDGINs are allosteric integration inhibitors CX04328 binds into a small molecule binding pocket in the dimer interface different from the strand transfer inhibitor binding pocket 1.84 Å co-crystal structure CX04328 does not alter the overall shape of the IN structure and competes with LEDGF (gray) for the binding to integrase. Christ et al., Nat. Chem. Biol. May 2010

Lead optimization compound classLEDGF/p75-INMTT/MT-4 IC 50 [µM] EC 50 [µM]CC 50 [µM]SI [CC 50 /EC 50 ] CX06387A0,0554+/-0,000520,114+/-0,064131,33+/-22, CX06458A1,570,33+/-071,66+/-14,3217 CX05272A0,75+/-0,440,44+/-0,2180,6+/-30,14183 CX05193A0,780,53+/-0,0754,29+/-8,28102 CX07522D1,080,53+/-0,2882+/-0155 CX06077A1,370,7838,549 CX05221A2,850,79+/-0,1782,94+/-34,16105 CX07707B0,991,17+/-0,1643,5+/-9,537 CX05192A0,621,21+/-0,3714,73+/-1,4212 CX06442B1,011,61+/-0,1240,33+/-16,9225 CX06579B41,8+/-14,21,8976+/-2540 CX06706B6,32,33+/-1,0438,33+/-15,6316 CX06645C17,852,91+/-0,4638,66+/-15,0113 CX07523D4,64,5+/-0,3114,5+/-12,525 CX06491C19,735, CX05271A3,25,379,815 CX06116A13,465,48+/-1,3558,5+/-25,511 CX06704B7,855,51+/-3,98200+/-48,5636 CX06542C10,885, CX07486C5,927,93+/-2,672,5+/-9,59 CX06544C13,3813, CX06581B62,6716,41563 CX06703B17,6821,16+/-1,8127+/-56 CX05792B2,8523, Multiple small molecules demonstrate a clear SAR.

Conclusions  Rational design has led to the development of LEDGINs, a novel class of antivirals  LEDGINs are potent inhibitors of the LEDGF/p75-IN interaction in vitro and in vivo.  Their lack of cross-resistance to raltegravir and elvitegravir as well as their allosteric nature demonstrate their potential as second generation integrase inhibitors  Medicinal chemistry optimization has led to a clear SAR of several compound classes  Preliminary ADMEtox data, pharmacokinetics, dynamics and metabolism assays demonstrate their potential for further clinical development. Nucleus Cytoplasm Reverse transcription complex Preintegration complex (PIC) TRN-SR2 LEDGF/p75 IN LEDGF/p75 IN

Thank you…. Molecular Medicine: Belete A. Desimmie, Barbara Van Remoortel, Nam Joo Van der Veken, Zeger Debyser Department of Pharmaceutical Sciences: Stefan Nicolet, Sergei Strelkov Laboratory for Biomolecular Modeling: Arnout Voet, Abel Jonckheer, Marc De Maeyer CD3 Leuven, CISTIM Leuven vzw: Damian Marchand, Arnaud Marchand, Dorothée Bardoit, Patrick Chaltin